en Melitracen

Melitracen
Clinical data
Trade names	Adaptol, Dixeran, Melixeran, Thymeol, Trausabun
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral, intramuscular injection
ATC code	N06AA14 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 3-(10,10-dimethylanthracen-9(10H)-ylidene)-N,N-dimethylpropan-1-amine;
CAS Number	5118-29-6 ;
PubChem CID	25382;
ChemSpider	23697 ;
UNII	Q7T0Y1109Z;
KEGG	D08171 ;
ChEMBL	ChEMBL110094 ;
CompTox Dashboard (EPA)	DTXSID4048274 ;
ECHA InfoCard	100.023.507
Chemical and physical data
Formula	C21H25N
Molar mass	291.438 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c3ccc2c(/C(c1c(cccc1)C2(C)C)=C/CCN(C)C)c3;
	InChI InChI=1S/C21H25N/c1-21(2)19-13-7-5-10-17(19)16(12-9-15-22(3)4)18-11-6-8-14-20(18)21/h5-8,10-14H,9,15H2,1-4H3 ; Key:GWWLWDURRGNSRS-UHFFFAOYSA-N ;
	(what is this?) (verify)

Melitracen (brand names Melixeran, Trausabun) is a tricyclic antidepressant (TCA), for the treatment of depression and anxiety.^[1]^[2]^[3]^[4] In addition to single drug preparations, it is also available as Deanxit, marketed by Lundbeck, a combination product containing both melitracen and flupentixol.^[5]^[6]^[7]^[8]

The pharmacology of melitracen has not been properly investigated and is largely unknown, but it is likely to act in a similar manner to other TCAs. Indeed, melitracen is reported to have imipramine and amitriptyline-like effects and efficacy against depression and anxiety, though with improved tolerability and a somewhat faster onset of action.^[9]^[10]

References

^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
^ Rhodes PH (1996). Dictionary of organic compounds. London: Chapman & Hall. ISBN 0-412-54090-8.
^ O'Neil MJ (2001). The Merck index: an encyclopedia of chemicals, drugs, and biologicals. Rahway, NJ: Merck Research Laboratories. ISBN 0-911910-13-1.
^ Holenz J, Díaz JL, Buschmann H (2007). "Marketed Drugs and Drugs in DevelopmentVela". In JM, Buschmann H, Holenz J, Párraga A, Torrens A (eds.). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 978-3-527-31058-6.
^ Muller NF, Dessing RP (1998). European Drug Index (4th ed.). Boca Raton: CRC Press. ISBN 3-7692-2114-1.
^ Van Moffaert M, Dierick M, De Meulemeester F, Vereecken A (1983). "Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol". Acta Psychiatrica Belgica. 83 (5): 525–539. PMID 6670581.
^ Bin Yaacob H (April 1985). "Flupenthixol and Melitracen in the management of trigeminal neuralgia". Dental Journal of Malaysia. 8 (2): 37–38. PMID 3917005.
^ Hashash JG, Abdul-Baki H, Azar C, Elhajj II, El Zahabi L, Chaar HF, Sharara AI (June 2008). "Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia". Alimentary Pharmacology & Therapeutics. 27 (11): 1148–1155. doi:10.1111/j.1365-2036.2008.03677.x. PMID 18331614. S2CID 40714136.
^ Aronson JK (2008). Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects). Amsterdam: Elsevier Science. ISBN 978-0-444-53266-4.
^ Krapcho J (1970). "Antidepressives and Stimulants". Annual Reports in Medicinal Chemistry. Vol. 5. Boston: Academic Press. ISBN 0-12-040505-9.

This article about an anxiolytic is a stub. You can help Wikipedia by expanding it.

[isbn3-88763-075-0-1] Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.

[isbn0-412-54090-8-2] Rhodes PH (1996). Dictionary of organic compounds. London: Chapman & Hall. ISBN 0-412-54090-8.

[isbn0-911910-13-1-3] O'Neil MJ (2001). The Merck index: an encyclopedia of chemicals, drugs, and biologicals. Rahway, NJ: Merck Research Laboratories. ISBN 0-911910-13-1.

[isbn3-527-31058-4-4] Holenz J, Díaz JL, Buschmann H (2007). "Marketed Drugs and Drugs in DevelopmentVela". In JM, Buschmann H, Holenz J, Párraga A, Torrens A (eds.). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 978-3-527-31058-6.

[isbn3-7692-2114-1-5] Muller NF, Dessing RP (1998). European Drug Index (4th ed.). Boca Raton: CRC Press. ISBN 3-7692-2114-1.

[pmid6670581-6] Van Moffaert M, Dierick M, De Meulemeester F, Vereecken A (1983). "Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol". Acta Psychiatrica Belgica. 83 (5): 525–539. PMID 6670581.

[pmid3917005-7] Bin Yaacob H (April 1985). "Flupenthixol and Melitracen in the management of trigeminal neuralgia". Dental Journal of Malaysia. 8 (2): 37–38. PMID 3917005.

[pmid18331614-8] Hashash JG, Abdul-Baki H, Azar C, Elhajj II, El Zahabi L, Chaar HF, Sharara AI (June 2008). "Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia". Alimentary Pharmacology & Therapeutics. 27 (11): 1148–1155. doi:10.1111/j.1365-2036.2008.03677.x. PMID 18331614. S2CID 40714136.

[isbn0-444-53266-8-9] Aronson JK (2008). Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects). Amsterdam: Elsevier Science. ISBN 978-0-444-53266-4.

[isbn0-12-040505-9-10] Krapcho J (1970). "Antidepressives and Stimulants". Annual Reports in Medicinal Chemistry. Vol. 5. Boston: Academic Press. ISBN 0-12-040505-9.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

Melitracen

See also

References